Clinical Trial Update: COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study [Phase 4]

View source ↗

Summary

Phase 4 study assessing chronic migraine treatments by combining CGRP monoclonal antibodies with onabotulinumtoxinA; current status is active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Headache
• Migraine

Drugs mentioned

• AIMOVIG (ERENUMAB-AOOE)
• Ajovy (fremanezumab)
• Botox (OnabotulinumtoxinA)
• Emgality (galcanezumab)
• VYEPTI (eptinezumab)

Snippet

Sponsor: Chicago Headache Center & Research Institute | Conditions: Chronic Migraine, Headache | Phase 4 | Status: ACTIVE_NOT_RECRUITING